Document N2o58KVwdkpEv87bB41Qz1JVE

To: Clegg, Patsy M SCC-DCS/22 <patsy.clegg@shell.com> From: Caitlin West <cwest@regesterlarkin.com> Cc: Colmer, Robert W SC-DCS/18 <Rob.Colmer@shell.com>; Zaayman, Johan H SCC- DCS/19 <Johan.Zaayman@shell.com> Bcc: Received Date: 2006-04-07 15:04:58 GMT Subject: Shanghai Benzene Study issue brief Patsy We have updated the Shanghai Benzene Study issue brief and put it into the revised Group issue template (changes are tracked). Please could you let me know if you are happy with the revisions? We will then run it past legal. Thanks for your help Best wishes Caitlin Caitlin West Senior Consultant Regester Larkin 16 Doughty Street London WC1N 2PL T: +44 (0)20 7831 3839 F: +44 (0)20 7831 3632 M: +44 (0)7779 616596 E: cwest@regesterlarkin.com W: www.regesterlarkin.com Reputation Risk Management SHELL-MCCLURG-063117 Email Disclaimer This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. They may contain legally privileged information, and may not be disclosed to anyone else. If you have received this email in error please send it to enquiries@regesterlarkin.com and delete all copies from your system. Attachments: Shanghai Benzene Study, 06.04.06.doc SHELL-MCCLURG-063118 Confidential Focal Point: Patsy Clegg Supporting Messages: The study, which began in 2001, was designed by independent epidemiological and toxicological investigators. The research protocols and the research itself are being overseen by a scientific and ethics review panel composed of 14 world-renowned, independent experts in the field. The research protocols also have been approved by independent review boards at Fudan University, the University of Colorado and Applied Health Sciences. The independent investigators conducting the study have full control over all interpretations and conclusions that may be drawn from the data when the study is completed, which is currently scheduled for 2007. Upon completion, the findings of the study will be peerreviewed and published by the researchers in scientific journals. A consortium of petroleum and chemical companies (the Benzene Health Research Consortium) funds this independent study. The consortium is administered by the American Petroleum Institute (API) and consists of BP, ChevronTexaco, ConocoPhillips, ExxonMobil and Shell Chemical LP. Shell has committed $4m to the $21 m study. Last updated: 06.04.2006 SHELL-MCCLURG-063119 Confidential Focal Point: Patsy Clegg A state-of-the-art clinical and molecular laboratory has been built on the Fudan Medical University campus to support the research project. The project includes three studies: case and control study on acute myelogenous leukemia (AML) and non-Hodgkin's lymphoma (NHL); study on aplastic anemia (AA), myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), and benzene poisoning disease progression; and study on molecular diseases of benzene exposed workers. The study will analyze benzene's effects on the blood and bone marrow, and its ability to cause cancer in workers. Issue Sensitivity In April 2005, the Shanghai Benzene Study identified a new health effect from high level, long-term exposure to benzene - myelodysplastic syndrome (MDS). As per section 8 (e) of the Toxic Substances Control Act (TSCA), Shell in the US communicated this information to the Environmental Protection Agency (EPA) and revised the benzene Material Substances Data Sheet (MSDS) to this effect. This information was also communicated to relevant customers [check]. Also in April 2005, the Houston Chronicle (a US campaigning newspaper) published an article alleging that the Shanghai Benzene study was biased because of funding from multinational oil companies, including Shell. The newspaper incorrectly claimed that results of the study had already been determined, and oil company sponsors would ensure that the results 'contradicted cancer claims'. There have been no follow-up articles since April 2005. The benzene business faces challenges regarding: Concern by local communities and NGOs about product health issues (which is high as benzene is classified as a human carcinogen); and Potential regulatory reviews of exposure levels. Regulators are particularly concerned about the impact of air pollution on health at present, and are keen to reduce exposure to chemicals such as benzene. There is a correlation between high levels of benzene exposure and acute myeloid leukaemia. The precise link between exposure and disease is not understood yet. There is disagreement in the scientific community about what level and what length of time a person has to be exposed to significantly increase that person's risk of developing cancer. Certain scientific studies have recently been published that allege exposure to benzene below accepted regulatory levels can cause adverse health effects: In December 2004, a paper published in Science reported that benzene had toxic effects on blood cells at 1 part per million, the level workers in the United States are allowed to be exposed to over an eight-hour work day. In August 2004, a study by the French National Institute of Health and Medical Research (published in Occupational and Environmental Medicine) reported that children living close to a petrol station were four times more likely to develop leukaemia. Last updated: 06.04.2006 SH ELL-MCCLU RG-063120